Tech Company Financing Transactions
Siren Biotechnology Funding Round
On 6/26/2026, Siren Biotechnology announced $8 million in funding from California Institute for Regenerative Medicine.
Transaction Overview
Company Name
Announced On
6/26/2026
Transaction Type
Debt
Amount
$8,000,000
Round
Undisclosed
Proceeds Purpose
The funding will support the conduct of that trial and the activities required to evaluate SRN-101 in patients.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
455 Mission Bay Blvd S 145
San Francisco, CA 94158
USA
San Francisco, CA 94158
USA
Phone
Undisclosed
Website
Email Address
Overview
Siren Biotechnology is sounding the alarm against cancer. The Company is pioneering Universal AAV Immuno-Gene Therapy, a novel therapeutic modality that combines the precision and durability of AAV gene therapy with the immune-modulating potential of cytokine-based approaches. Siren's platform is designed to support localized, sustained immune activation across solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nicole Paulk
VP - Bus. Development
Nathalie Clément
VP - Bus. Development
Akela Kuwahara
VP - Regulatory Affairs
Christopher Novashinski
VP - Regulatory Affairs
Tracy TreDenick-Fricke
Browse more venture capital transactions:
Prev: 6/26/2026: Airwallex venture capital transaction
Next: 6/26/2026: Aristo Intelligence venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs